Indian company Dhiti Omics now live on SOPHiA DDM

image credit- shutterstock

SOPHiA GENETICS announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDM Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities.

Dhiti Omics specializes in molecular diagnostic and genetic testing. By implementing SOPHiA DDM for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers with actionable information on mutations and biomarkers across hundreds of genes.

SOPHiA DDM for SureSelect Cancer CGP application combines Agilent's genomic profiling assay kit with the SOPHiA DDM platform. Launched in 2023, the SureSelect Cancer CGP application offers comprehensive genomic profiling. With the SOPHiA DDM AI Platform, Dhiti Omics will have an integrated solution for rapid and accurate insights on the basis of the latest guidelines reflecting relevant biomarkers, and enabling Dhiti Omics to facilitate novel approaches to cancer research and diagnostics.

Sudha N. Rao, Ph.D., Founder and Director of Dhiti Omics Technologies said, "Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximize insights from comprehensive genomic profiling data. This will ensure we're delivering the fastest and most accurate diagnostics to our customer base."